Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

Similar documents
Viral Hepatitis in Reproductive Health

Hepatitis B vaccination worldwide: Lessons learnt and the way forward

Need for Chronic Viral Hepatitis Monitoring System

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis

Viral Hepatitis: A Global Snapshot of Challenges and Opportunities

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

CANCER FACT SHEETS: BREAST CANCER

Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD

Epidemiology of hepatitis B and D in Greece

CANCER FACT SHEETS: LIVER CANCER

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

CANCER FACT SHEETS: STOMACH CANCER

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

Understanding your epidemic: WHO tools for hepatitis surveillance

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

The epidemiology of tuberculosis

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

Viral hepatitis and Hepatocellular Carcinoma

Immunization Update & focus on meningococcal vaccine PART 1

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Measles and Rubella Global Update SAGE 19 October 2017

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Global Epidemiology and Prevention of Hepatitis B

Bible Class: Hepatitis B Virus Infection

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

Management of Hepatocellular Carcinoma in Africa CWN Spearman

EVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN)

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

EAST LONDON INTEGRATED CARE

Epidemiological profiles of viral hepatitis in Italy Effects of migration

Test Name Results Units Bio. Ref. Interval

March 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D

Viral Hepatitis Burden and Policy Directions in the European Region of WHO

511,000 (57% new cases) ~50,000 ~30,000

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

The Global Movement to Eliminate Viral Hepatitis. John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Name of the presenter

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

The Hepatitis B Vaccine: What Went Wrong?

Hepatitis C. Core slides

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Global Rotavirus Surveillance Network

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

HPV vaccine the global perspective

HBV in New Zealand Community HBV screening to long-term follow-up

HEPATITIS B: Edina Amponsah-Dacosta. Post-Vaccination Surveillance JEFFREY MPHAHLELE. On behalf of. Head

Test Name Results Units Bio. Ref. Interval

HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?

HBV/HIV Co-infection in sub-saharan Africa CWN Spearman

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Hepatocellular Carcinoma (HCC): Burden of Disease

Fact sheets on sustainable development goals: health targets. Viral Hepatitis

CHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND

ABC of Viral Hepatitis. Mark Thursz

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Natural History of Chronic Hepatitis B

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Test Name Results Units Bio. Ref. Interval

HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

Methodological issues in the use of anthropometry for evaluation of nutritional status

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review

An Update HBV Treatment

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees

Estimating the impact of HBV vaccination policies

Mortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL

Report on the 3rd International HIV/Viral Hepatitis Co-Infection Meeting

JMSCR Volume 03 Issue 01 Page January 2015

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

Viral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN

Mathematical Model of Hepatitis B in. the Bosomtwe District of Ashanti Region, Ghana

Can we treat our way out of the HIV epidemic?

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Call to Action. Global and Regional Hepatitis Action Plans: Opportunities and considerations for China

Hepatitis B infection

Maitines septiembre de 2011 Francisco Jorquera Plaza

Update of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital

Control of Hepatitis B and the Revolution in Global Immunization. Mark A. Kane MD, MPH Mercer Island, WA

HIV AND HEPATITIS B/C CO-INFECTION IN KWAZULU-NATAL FROM 2002 TO 2010: A RETROSPECTIVE DATABASE ANALYSIS

MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME

Seroprevalence of Hepatitis B Surface Antigen (HBsAg) Among Patients at a Tertiary Care Hospital in Mumbai, India

HPV Vaccination Global policy perspectives Vacuna VPH Perspectivas de la política de vacunación mundial

Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific

Transcription:

Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000 HCV 800000 600000 400000 200000 HBV 0 HIV TB Malaria Viral hepatitis Chen DS et al., Lancet Infect Dis, 2015

From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000 HCV 800000 600000 400000 200000 HBV 0 HIV TB Malaria Viral hepatitis Chen DS et al., Lancet Infect Dis, 2015

2016 2030 Finally targeted!!

Reducing: - the incidence of new chronic infection by 90% - the mortality from chronic infection by 65%

To increase the treatment coverage in chronic carriers eligible for antiviral therapy 2015 8% 2030 80% Reducing: - the incidence of new chronic infection by 90% - the mortality from chronic infection by 65%

Prevalence of HBsAg, 1990-2013 Schweitzer A et al., Lancet, 2015

Incidence of hepatocellular carcinoma, 2008 El-Serag HB et al., New Engl J Med, 2011

1. MOST PEOPLE HAVE BEEN EXPOSED TO HBV DURING CHILDHOOD

Modes of Transmission East Asia Sub-Saharan Africa Childhood (60%) MTCT (40%) Childhood (90%) MTCT (10%) Edmunds WJ et al., Epidemiol Infect, 1996

Sero-prevalence in children The Gambia

Sero-prevalence in children The Gambia Anti-HBc (+) only HBsAg(+) HBeAg(-) HBsAg(+) HBeAg(+) MTCT Whittle H et al., J Infect Dis, 1990

Sero-prevalence in children The Gambia Anti-HBc (+) only HBsAg(+) HBeAg(-) HBsAg(+) HBeAg(+) MTCT Horizontal transmission Whittle H et al., J Infect Dis, 1990

Sero-prevalence in children The Gambia Anti-HBc (+) only HBsAg(+) HBeAg(-) HBsAg(+) HBeAg(+) MTCT Horizontal transmission Whittle H et al., J Infect Dis, 1990

>75% have been exposed to HBV during childhood Kiire CF, Gut, 1996

2. TRANSMISSION DURING ADULTHOOD IS A MINOR ISSUE

Acute hepatitis B Case series in Senegal, Chad, and Nigeria Only 0-22% carried anti-hbc IgM Difficult to recruit patients Pillot J et al., 1992, J Hepatol Crato M et al., 1993, Dakar Med Coursaget P et al., 1998, Am J Trop Med Hyg Buisson Y et al., 2000, J Gen Virol

Co-infection with HCV or HIV Major mode of transmission is different Prevalence of co-infection with HCV or HIV is not particularly high compared to those without chronic HBV infection In a population-based cohort of chronic HBV infection in The Gambia: HCV 0.3% (1/301) HIV 1.0% (3/301) Hoffmann CJ & Thio CL, Lancet Infect Dis, 2007 Shimakawa Y et al., Gut, 2016

Immunization coverage with 3rd dose of HepB vaccines in infants, 2014 0 1,050 2,100 4,200 Kilometers Source: WHO/UNICEF coverage estimates 2015 revision. July 2015. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization Date of slide: 16 July 2015 <50% (7 countries or 4%) 50-79% (30 countries or 16%) 80-89% (32 countries or 17%) >=90% (115 countries or 62%) Not available / HepB not introduced or no coverage data available (10 countries or 5%) Not applicable The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2015. All rights reserved

Immunization coverage with 3rd dose of HepB vaccines in infants, 2014 Potential for epidemiological shift Past: >80% had naturally acquired & <20% of adults were susceptible 0 1,050 2,100 4,200 Kilometers Future?: High vaccine coverage: eliminate HBV Future?: Inadequate coverage: increasing age at HBV infection, Source: WHO/UNICEF coverage estimates 2015 revision. July 2015. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization Date of slide: 16 July 2015 <50% (7 countries or 4%) resulting in more 50-79% acute (30 countries or hepatitis 16%) 80-89% (32 countries or 17%) >=90% (115 countries or 62%) Not available / HepB not introduced or no coverage data available (10 countries or 5%) Not applicable The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2015. All rights reserved

3. LIVER CANCER IS A MAJOR PUBLIC HEALTH PROBLEM

Cancer deaths in Africa Jemal A et al., Cancer, 2012

In The Gambia Hepatocellular carcinoma (HCC) is the most frequent type of cancer 60% are due to HBV infection Only <1% had heard about HBV infection and had been tested for HBV in the past Most people remains undiagnosed until later stages of disease when prognosis is poor and treatment options are limited Shimakawa Y et al., Int J Cancer 2013 Kirk GD et al., Hepatology 2004 Lemoine M, Shimakawa Y, et al., Lancet Glob Health 2016

No cure, no care! HCC patients referred to Liver Clinic (n=25) Median score Pain 4/5 (IQR: 3-5) Worry 5/5 (IQR: 2-5) None Shimakawa Y et al., Palliat Med 2015 Codeine

Does HBV-related hepatocellular carcinoma occur at an early age in Africa??

N Mean age at HBV-related HCC Median age of population Europe 1039 58.0 41.7 USA 7060 56.0 38.0 East Asia 15871 54.5 37.9 Sub-Saharan Africa 126 38.9 18.3

N Mean age at HBV-related HCC Median age of population Europe 1039 58.0 41.7 USA 7060 56.0 38.0 East Asia 15871 54.5 37.9 Sub-Saharan Africa 126 38.9 18.3

Need to take account of: 1- Difference in the age distribution of underlying population 2- Higher risk for competing causes of death in Africa The best way to address this question ÞAge-specific incidence rates of HCC in population-based cohort of chronic HBV carriers Þ Age-specific incidence rates of HCC in general population (with similar HBV prevalence) Shimakawa Y & Lemoine M. Lancet Gastroenterol Hepatol, 2017

Need to take account of: 1- Difference in the age distribution of underlying population 2- Higher risk for competing causes of death in Africa The best way to address this question Þ Age-specific incidence rates of HCC in population-based cohort of chronic HBV carriers Þ Age-specific incidence rates of HCC in general population (with similar HBV prevalence) Shimakawa Y & Lemoine M. Lancet Gastroenterol Hepatol, 2017

Incidence rates (per 100 000 carrier-years) 1800 1600 1400 1200 1000 800 600 400 200 0 Age-specific incidence rates of HCC in male chronic HBV carriers in Gambia 25-34 35-44 45-54 55-64 65+ Shimakawa Y & Lemoine M. Lancet Gastroenterol Hepatol, 2017

600 Age-specific incidence rates of HCC in men in The Gambia and in China Incidence rates (per 100 000) 500 400 300 200 100 0 0-14 15-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ The Gambia China Globocan 2012 (http://globocan.iarc.fr/default.aspx) Shimakawa Y & Lemoine M. Lancet Gastroenterol Hepatol, 2017

Summary Most of people had been exposed to HBV during childhood Horizontal >> Mother-to-child Adulthood transmission is rare, but may change with inadequate infant vaccine coverage HCC: no cure, no care Early age at HCC development: questionnable